Objective: To investigate the expression of B7-H3 and B7-H4 and their clinical implications in human gallbladder carcinoma.
Patients And Methods: The expression of B7-H3 and B7-H4 in the 252 samples (126 cases of chronic cholecystitis and 126 cases of gallbladder cancer) was detected by the streptavidin-peroxidase immunohistochemical method, and their associations with tumor classification, clinical grade, and recurrence were assessed.
Results: In chronic cholecystitis tissue, B7-H3 and B7-H4 were not detected. In 126 cases of gallbladder carcinoma, the positive rates of B7-H3 and B7-H4 expression were 66.67% and 69.05% respectively (p < 0.05). The positive rate of B7-H3 in the primary-onset group was 53.57%, and that in recurrence group was 92.86% (p < 0.05). The positive rate of B7-H4 in the primary-onset group was 85.19%, and that in recurrence group was 40.00% (p < 0.05). Expression of B7-H3 was consistent with B7-H4 expression in gallbladder carcinoma.
Conclusions: B7-H3 and B7-H4 were up-regulated in gallbladder cancer; the high expression of B7-H3 may contribute to the early diagnosis of gallbladder carcinoma and the assessment of postoperative survival and recurrence. B7-H4 may play an important role in the incidence of gallbladder cancer. B7-H3 and B7-H4 may play a synergetic role in gallbladder carcinoma. Combined tests were available for the diagnosis, degree assessment and prognosis of gallbladder carcinoma, which may be a new target for molecular targeted therapy of gallbladder carcinoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Immune marker expression and prognosis of early breast cancer expressing HER3.
Eur J Cancer
December 2024
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; Translational Medicine, Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. Electronic address:
Introduction: There is a strong rationale for targeting HER3, as HER3 contributes to tumorigenesis and treatment resistance. However, the prognostic role of HER3 and their association with immunoregulatory protein expression has not been established.
Methods: The main objective of this study was to investigate the prognostic role of HER3 expression and identify immunoregulatory marker expression according to HER3 status.
Expression of B7-H3 and B7-H4 in Gastric Gastrointestinal Stromal Tumors.
Appl Immunohistochem Mol Morphol
November 2024
University of Yamanashi, Chuo, Yamanashi, Japan.
Article Synopsis
- - Gastric gastrointestinal stromal tumors (GISTs) are tumors in the GI tract that originate from specific cells, and their treatment has significantly improved with imatinib, a drug that targets a specific protein called KIT, but many patients eventually see their disease progress.
- - There's a need for new treatment methods for GISTs that no longer respond to imatinib, as most patients face progression of their disease within a few years of treatment.
- - This study focuses on the role of immune checkpoint proteins B7-H3 and B7-H4 in gastric GISTs, finding that B7-H3 is expressed in nearly all GIST samples examined, indicating it may help tumors evade the immune system.
Multiplexed Spatial Imaging at the Single-Cell Level Reveals Mutually Exclusive Expression of B7 Family Proteins.
Lab Invest
October 2024
Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Targeting novel inhibitory ligands beyond anti-PD-1 and PD-L1 and CTLA-4 therapies is essential for the next decade of the immunotherapy era. Agents for the B7 family molecules B7-H3, B7-H4, and B7-H5 are emerging in clinical trial phases; therefore, further accumulation of evidence from both clinical and basic aspects is vital. Here, we applied a 7-color multiplexed imaging technique to analyze the profile of B7 family B7-H3/B7-H4/B7-H5 expression, in addition to PD-L1, and the spatial characteristics of immune cell infiltrates in urothelial carcinoma (UC).
View Article and Find Full Text PDFDouble agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting.
Crit Rev Oncol Hematol
October 2024
Division of Hematology and Oncology, Department of Medicine, University of Alabama, Birmingham, United States. Electronic address:
Antibody-drug conjugates (ADCs) have high specificity with lesser off-target effects, thus providing improved efficacy over traditional chemotherapies. A total of 14 ADCs have been approved for use against cancer by the US Food and Drug Administration (FDA), with more than 100 ADCs currently in clinical trials. Of particular interest ADCs targeting immune antigens PD-L1, B7-H3, B7-H4 and integrins.
View Article and Find Full Text PDFDifferential Immune Checkpoint Protein Expression in HNSCC: The Role of HGF/MET Signaling.
Int J Mol Sci
July 2024
Department of Oral and Maxillofacial Plastic Surgery, University Hospital Wuerzburg, D-97070 Würzburg, Germany.
Although inhibitors targeting the PD1/PD-L1 immune checkpoint are showing comparably good outcomes, a significant percentage of head and neck squamous cell carcinoma (HNSCC) patients do not respond to treatment. Apart from using different treatment strategies, another possibility would be to target other immune checkpoints operating in these non-responding tumors. To obtain an overview of which checkpoint ligands are expressed on HNSCC tumor cells and if these ligands are affected by HGF/MET signaling, we used mRNA sequencing and antibody-based techniques for identifying checkpoint ligands in six HNSCC tumor cell lines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!